stockrowHumacyte, Inc.
HUMA Healthcare Biotechnology
Humacyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, up 30.2% from fiscal 2022.
- Revenue
- +34.9%
- EPS
- +33.3%
- Free cash flow
- +17.9%
- Total debt
- +437.5%
Quarter to June 2026, against a year earlier
Follow HUMA
Alert me
Humacyte, Inc. (HUMA) EV/Sales
As of 6 November 2026, Humacyte, Inc. (HUMA) trades at a EV/Sales of 41.4×. Over the past ten years it has ranged from 0.0× (September 2021) to 670× (July 2024); the current reading is higher than 17% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 80.4× | 20.05% |
| FY2022 | 66.9× | (25.03%) |
| FY2021 | 89.3× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 78.9× | 17.34% |
| Mar 2026 | 67.3× | (16.28%) |
| Dec 2025 | 80.4× | (55.41%) |
| Sep 2025 | 180× | (48.80%) |
| 11 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OTLK Outlook Therapeutics, Inc. compare | −66.1× |
| FHTX Foghorn Therapeutics Inc. compare | −0.4× |
| NKTX Nkarta, Inc. compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| ENGN enGene Therapeutics Inc compare | n/m |
| VYGR Voyager Therapeutics, Inc. compare | 0.4× |
| CDXS Codexis, Inc. compare | 1.0× |
| HUMA Humacyte, Inc. | 41.4× |
| ARMP Armata Pharmaceuticals, Inc. compare | 69.2× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)